An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series.

Background: Current treatments for chronic lichen planus (LP) are often ineffective and may have significant adverse side effects. An alternative safe and effective treatment for recalcitrant LP is needed.

Objectives: We sought to study the safety and efficacy of apremilast in the treatment of moderate to severe LP.

Monitoring for medication errors in outpatient settings.

Background: Vigilant reporting of medication errors and adverse drug events (ADEs) is needed to understand and reduce the extent of this problem in dermatology. Various systems are already in place in inpatient settings.

Objective: To review existing medication error reporting systems related to outpatient settings with emphasis on topical medications associated with dermatological diseases.

Cytochrome P450 epoxygenases provide a novel mechanism for penile erection.

Erectile dysfunction (ED) is estimated to affect more than 30 million American men and 152 million men worldwide. Therapeutic agents targeting the nitric oxide/cyclic GMP signaling pathway have successfully treated patients with ED; however, the efficacies of these treatments are significantly lower in specific populations such as patients with diabetes. The goal of this study was to discover and identify new endothelium-derived relaxing factors involved in the regulation of erectile function, providing alternative therapeutic targets for treatment of ED.